September 15, 2015

Acorda Therapeutics Inc. v. Par Pharmaceutical Inc.

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. January 21, 2016

    Acorda Strikes Patent Deal To Delay Par's Generic Ampyra

    Acorda Therapeutics Inc. said Wednesday it has ended its Delaware federal court suit accusing Par Pharmaceutical Inc. of flouting four patents covering the multiple sclerosis drug Ampyra after the companies agreed to a settlement that pushes back Par's proposed generic version until approximately 2027.


Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!